A Scripps Research vaccine candidate kept vaccinated mice breathing nearly normally after fentanyl exposure and cut fentanyl levels in their brains by about 70% versus unvaccinated mice.
Four doses over eight weeks trained antibodies to recognize a shared molecular fingerprint across the fentanyl class, rather than one exact drug structure.
Those antibodies bound tightly to fentanyl and variants including carfentanil, China White, acetylfentanyl and furanylfentanyl, while sparing clinical opioids such as morphine and oxycodone.
The approach aims to outpace black-market designer drugs that are constantly modified to evade detection, offering a potential overdose-prevention tool for people at high risk if human trials succeed.
With promising mouse trials, what hurdles remain before this vaccine can save human lives?
Can a vaccine truly win the chemical arms race against black-market fentanyl variants?
Breakthrough Fentanyl Vaccine Advances to Human Trials Amid Opioid Crisis
Overview
The Scripps Research fentanyl vaccine has reached a major milestone by advancing to human trials, with Phase I starting in the Netherlands in January 2026 and results expected by early 2027. If the vaccine proves safe, researchers plan to move quickly to Phase II trials in the United States. This vaccine works as an immunopharmacotherapy, aiming to sequester fentanyl in the body and prevent opioid dependence, withdrawal, and accidental overdose. By offering a new approach to addiction treatment and overdose prevention, the vaccine could become a vital tool in addressing the ongoing opioid crisis.